Effects of a novel Nodal-targeting monoclonal antibody in melanoma

Oncotarget

Volumn 6, Issue 33, 2015, Pages 34071-34086

  Strizzi, Luigi ^a,b   Sandomenico, Annamaria ^c   Margaryan, Naira V ^a   Focà, Annalia ^c   Sanguigno, Luca ^c   Bodenstine, Thomas M ^a   Chandler, Grace S ^a   Reed, David W ^a   Gilgur, Alina ^a   Seftor, Elisabeth A ^a   Seftor, Richard E B ^a,b   Khalkhali Ellis, Zhila ^a,b   Leonardi, Antonio ^c   Ruvo, Menotti ^c   Hendrix, Mary J C ^a,b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antibody; Cancer; ELISA; Nodal; Therapy

Indexed keywords

B RAF KINASE; CYCLIN B1; DABRAFENIB; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3D1; PROTEIN NODAL; PROTEIN P27; SMAD2 PROTEIN; UNCLASSIFIED DRUG; CCNB1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMIDAZOLE DERIVATIVE; NODAL PROTEIN, HUMAN; OXIME; SMAD2 PROTEIN, HUMAN;

A375SM CELL LINE; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; C8161 CELL LINE; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MELANOMA; MICE; NODAL PROTEIN; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; SMAD2 PROTEIN; SURFACE PLASMON RESONANCE;

EID: 84941222229     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6049     Document Type: Article

References (53)

1. Song X, Zhao Z, Barber B, Farr AM, Ivanov B and Novich M. Overall survival in patients with metastatic melanoma. Curr Med Res Opin. 2015; 31:987-991.
2. Gogas HJ, Kirkwood JM and Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007; 109:455-464.
3. Han SF, Liu P, Zhang W, Bu L, Shen M, Li H, Fan YH, Cheng K, Cheng HX, Li CX and Jia GL. The oppositedirection modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol. 2007; 124:90-97.
4. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, 3rd, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, et al. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014; 12:621-629.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-723.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507-2516.
7. Ascierto PA, Minor D, Ribas A, Lebbe C, O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ, Hamid O, Amaravadi R, Simeone E, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013; 31:3205-3211.
8. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367:107-114.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443-2454.
10. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372:30-39.
11. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward NK, Johansson P, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014; 5:5694.
12. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015.
13. Klinac D, Gray ES, Millward M and Ziman M. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013; 3:54.
14. Roesch A. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene. 2015; 34:2951-2957.
15. Ascierto PA. Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma. Cancer Immunol Immunother. 2015; 64:271-274.
16. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT and Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006; 5:1136-1144.
17. Strizzi L, Hardy K, Seftor E, Costa F, Kirschmann D, Seftor R, Postovit L and Hendrix M. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res. 2009; 69:7131-7134.
18. Shen MM. Nodal signaling: developmental roles and regulation. Development. 2007; 134:1023-1034.
19. Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, Arndt K, Bonaldo Mde F, Soares MB, Hendrix MJ. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics. 2009;1:387-98.
20. Strizzi L, Hardy KM, Kirsammer GT, Gerami P and Hendrix MJ. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest. 2011; 91:819-824.
21. Strizzi L, Hardy K, Margaryan N, Hillman D, Seftor E, Chen B, Geiger X, Thompson E, Lingle W, Andorfer C, Perez E and Hendrix M. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Research. 2012; 14:R75.
22. Lawrence M, Margaryan N, Loessner D, Collins A, Kerr K, Turner M, Seftor E, Stephens C, Lai J, BioResource A, Postovit L, Clements J and Hendrix M. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate. 2011; 71:1198-1209.
23. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, Wheaton WW, Abbott DE, Seftor RE and Hendrix MJ. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci U S A. 2008; 105:4329-4334.
24. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C, Seftor RE, Seftor EA and Hendrix MJ. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol. 2009; 4:67-78.
25. Kirsammer G, Strizzi L, Margaryan NV, Gilgur A, Hyser M, Atkinson J, Kirschmann DA, Seftor EA and Hendrix MJ. Nodal signaling promotes a tumorigenic phenotype in human breast cancer. Semin Cancer Biol. 2014; 29:40-50.
26. Hardy KM, Strizzi L, Margaryan NV, Gupta K, Murphy GF, Scolyer RA and Hendrix MJ. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma. Mol Cancer Res. 2015; 13:670-680.
27. Focà A, Sanguigno L, Focà G, Strizzi L, Iannitti R, Palumbo R, Hendrix MJC, Leonardi A, Ruvo M, Sandomenico A. New anti-Nodal monoclonal antibodies targeting the Nodal pre-helix loop involved in Cripto-1 binding. Int J Mol Sci 2015; 16: 21342-21362.
28. Calvanese L, Sandomenico A, Caporale A, Foca A, Foca G, D'Auria G, Falcigno L and Ruvo M. Conformational features and binding affinities to Cripto, ALK7 and ALK4 of Nodal synthetic fragments. J Pept Sci. 2015; 21:283-293.
29. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, Nickoloff BJ, Topczewski J and Hendrix MJ. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nature Med. 2006; 12:925-932.
30. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155:739-752.
31. Lo JA and Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science. 2014; 346:945-949.
32. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150:251-263.
33. Murphy GF, Wilson BJ, Girouard SD, Frank NY and Frank MH. Stem cells and targeted approaches to melanoma cure. Mol Aspects Med. 2014; 39:33-49.
34. Vallier L, Reynolds D and Pedersen RA. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev Biol. 2004; 275:403-421.
35. Li FZ, Dhillon AS, Anderson RL, McArthur G and Ferrao PT. Phenotype switching in melanoma: implications for progression and therapy. Front Oncol. 2015; 5:31.
36. Quail DF, Zhang G, Findlay SD, Hess DA and Postovit LM. Nodal promotes invasive phenotypes via a mitogenactivated protein kinase-dependent pathway. Oncogene. 2014; 33:461-473.
37. Huang S, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, Groenendijk FH, Mittempergher L, Nijkamp W, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell. 2012; 151:937-950.
38. Khalkhali-Ellis Z, Kirschmann DA, Seftor EA, Gilgur A, Bodenstine TM, Hinck AP and Hendrix MJ. Divergence(s) in nodal signaling between aggressive melanoma and embryonic stem cells. Int J Cancer. 2015; 136:E242-251.
39. Calvanese L, Marasco D, Doti N, Saporito A, D'Auria G, Paolillo L, Ruvo M and Falcigno L. Structural investigations on the Nodal-Cripto binding: a theoretical and experimental approach. Biopolymers. 2010; 93:1011-1021.
40. Calvanese L, Falcigno L and D'Auria G. Essential dynamics analysis captures the concerted motion of the integrinbinding site in jerdostatin, an RTS disintegrin. Biopolymers. 2015; 103:158-166.
41. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E and Robert C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013; 24:1697-1703.
42. Johnsson B, Lofas S and Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 1991; 198:268-277.
43. Gaddameedhi S, Kemp MG, Reardon JT, Shields JM, Smith-Roe SL, Kaufmann WK and Sancar A. Similar nucleotide excision repair capacity in melanocytes and melanoma cells. Cancer research. 2010; 70:4922-4930.
44. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L and Hendrix MJ. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res. 2010; 70:10340-10350.
45. Kozlowski JM, Hart IR, Fidler IJ and Hanna N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst. 1984; 72:913-917.
46. Bodenstine TM, Seftor RE, Seftor EA, Khalkhali-Ellis Z, Samii NA, Monarrez JC, Chandler GS, Pemberton PA and Hendrix MJ. Internalization by multiple endocytic pathways and lysosomal processing impact maspin-based therapeutics. Mol Cancer Res. 2014; 12:1480-1491.
47. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003;112:575-87.
48. Yu L, Harms PW, Pouryazdanparast P, Kim DS, Ma L, Fullen DR. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Mod Pathol. 2010; 23:1209-14.
49. Lee CC, Jan HJ, Lai JH, Ma HI, Hueng DY, Lee YC, Cheng YY, Liu LW, Wei HW, Lee HM. Nodal promotes growth and invasion in human gliomas. Oncogene. 2010; 29:3110-23.
50. Fu G, Peng C. Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells. Oncogene. 2011; 30:3953-66.
51. Jamil S, Cedervall J, Hultman I, Ali R, Margaryan NV, Rasmuson A, Johnsen JI, Sveinbjörnsson B, Dalianis T, Kanter L, Orrego A, Strizzi L, Hendrix MJ, et al. Neuroblastoma cells injected into experimental mature teratoma reveal a tropism for embryonic loose mesenchyme. Int J Oncol. 2013; 43:831-8.
52. Duan W, Li R, Ma J, Lei J, Xu Q, Jiang Z, Nan L, Li X, Wang Z, Huo X, Han L, Wu Z, Wu E, et al. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Oncotarget. 2015; 6:1490-506.
53. Kong B, Wang W, Esposito I, Friess H, Michalski CW, Kleeff J. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Pancreatology. 2015; 15:156-61.